Skip to main content
SpringerLink
Log in

Antibody Engineering in Translational Medicine

  • Chapter
  • First Online:
Engineering in Translational Medicine

  • 2581 Accesses

Abstract

Antibodies (Abs) are a major constituent of the human immune system and have become an important class of therapeutics in cancer and inflammatory diseases. Antibody engineering technologies aim at the development of new generations of antibody-based drugs with more favorable properties, including higher potency or improved safety profiles. This chapter provides an overview over current strategies to tailor Abs for medical applications. While some of the engineering technologies improve the inherent features of the antibody—like target specificity, effector functions, or pharmacokinetics—others empower the antibody with additional mechanisms of action. The latter category includes the development of antibody–drug conjugates (ADCs), radioimmunoconjugates, or bispecific Abs. These novel antibody-based therapeutics will likely have a big impact on the future treatment of many diseases, but especially in cancer therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Owen JA, Punt J, Stranford SA, Jones PP, Kuby J (2013) Kuby immunology, 7th edn. W.H Freeman, New York

    Google Scholar 

  2. Market E, Papavasiliou FN (2003) V(D)J recombination and the evolution of the adaptive immune system. PLoS Biol 1(1):E16

    Google Scholar 

  3. Diaz M, Casali P (2002) Somatic immunoglobulin hypermutation. Curr Opin Immunol 14(2):235–240

    Article  Google Scholar 

  4. Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L (2012) Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol 12(5):615–622

    Article  Google Scholar 

  5. Reichert JM (2013) Which are the antibodies to watch in 2013? MAbs 5(1):1–4

    Article  MathSciNet  Google Scholar 

  6. Reichert JM, Dhimolea E (2012) The future of antibodies as cancer drugs. Drug Discov Today 17(17–18):954–963

    Article  Google Scholar 

  7. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495–497

    Article  Google Scholar 

  8. Mirick GR, Bradt BM, Denardo SJ, Denardo GL (2004) A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging 48(4):251–257

    Google Scholar 

  9. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81(21):6851–6855

    Article  Google Scholar 

  10. Boulianne GL, Hozumi N, Shulman MJ (1984) Production of functional chimaeric mouse/human antibody. Nature 312(5995):643–646

    Article  Google Scholar 

  11. Neuberger MS, Williams GT, Mitchell EB, Jouhal SS, Flanagan JG, Rabbitts TH (1985) A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature 314(6008):268–270

    Article  Google Scholar 

  12. Brüggemann M, Winter G, Waldmann H, Neuberger MS (1989) The immunogenicity of chimeric antibodies. J Exp Med 170(6):2153–2157

    Article  Google Scholar 

  13. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321(6069):522–525

    Article  Google Scholar 

  14. Riechmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332(6162):323–327

    Article  Google Scholar 

  15. Padlan EA, Abergel C, Tipper JP (1995) Identification of specificity-determining residues in antibodies. FASEB J 9(1):133–139

    Google Scholar 

  16. Padlan EA (1991) A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol 28(4–5):489–498

    Article  Google Scholar 

  17. Pedersen JT, Henry AH, Searle SJ, Guild BC, Roguska M, Rees AR (1994) Comparison of surface accessible residues in human and murine immunoglobulin Fv domains. Implication for humanization of murine antibodies. J Mol Biol 235(3):959–973

    Article  Google Scholar 

  18. Baker MP, Jones TD (2007) Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel 10(2):219–227

    Google Scholar 

  19. Lazar GA, Desjarlais JR, Jacinto J, Karki S, Hammond PW (2007) A molecular immunology approach to antibody humanization and functional optimization. Mol Immunol 44(8):1986–1998

    Article  Google Scholar 

  20. McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348(6301):552–554

    Article  Google Scholar 

  21. Clackson T, Hoogenboom HR, Griffiths AD, Winter G (1991) Making antibody fragments using phage display libraries. Nature 352(6336):624–628

    Article  Google Scholar 

  22. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS (1996) Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 14(3):309–314

    Article  Google Scholar 

  23. Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15(6):553–557

    Article  Google Scholar 

  24. Green LL (1999) Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 231(1–2):11–23

    Article  Google Scholar 

  25. Green LL, Hardy MC, Maynard-Currie CE, Tsuda H, Louie DM, Mendez MJ, Abderrahim H, Noguchi M, Smith DH, Zeng Y, David NE, Sasai H, Garza D, Brenner DG, Hales JF, McGuinness RP, Capon DJ, Klapholz S, Jakobovits A (1994) Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 7(1):13–21

    Article  Google Scholar 

  26. Lonberg N (2005) Human antibodies from transgenic animals. Nat Biotechnol 23(9):1117–1125

    Article  Google Scholar 

  27. Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, Kuo CC, Mashayekh R, Wymore K, McCabe JG et al (1994) Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368(6474):856–859

    Article  Google Scholar 

  28. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9(10):767–774

    Article  Google Scholar 

  29. Dall’Acqua WF, Kiener PA, Wu H (2006) Properties of human IgG1 s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281(33):23514–23524

    Article  Google Scholar 

  30. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR (2010) Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28(2):157–159

    Article  Google Scholar 

  31. Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, de Haas M, Jonsdottir I, van der Schoot CE, Vidarsson G (2011) Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun 2:599

    Article  Google Scholar 

  32. Lu Y, Harding SE, Rowe AJ, Davis KG, Fish B, Varley P, Gee C, Mulot S (2008) The effect of a point mutation on the stability of IgG4 as monitored by analytical ultracentrifugation. J Pharm Sci 97(2):960–969

    Article  Google Scholar 

  33. Vaccaro C, Zhou J, Ober RJ, Ward ES (2005) Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 23(10):1283–1288

    Article  Google Scholar 

  34. Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93(11):2645–2668

    Article  Google Scholar 

  35. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA (2010) Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 21(12):2153–2163

    Article  Google Scholar 

  36. Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, Hattori K (2010) Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 23(5):385–392

    Article  Google Scholar 

  37. Sharifi J, Khawli LA, Hornick JL, Epstein AL (1998) Improving monoclonal antibody pharmacokinetics via chemical modification. Q J Nucl Med 42(4):242–249

    Google Scholar 

  38. Vincent KJ, Zurini M (2012) Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates. Biotechnol J 7(12):1444–1450

    Article  Google Scholar 

  39. Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, Moriyama C, Watanabe T, Takubo R, Doi Y, Wakabayashi T, Hayasaka A, Kadono S, Miyazaki T, Haraya K, Sekimori Y, Kojima T, Nabuchi Y, Aso Y, Kawabe Y, Hattori K (2010) Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 28(11):1203–1207

    Google Scholar 

  40. Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, Geng T, Lindquist K, Casas MG, Boustany LM, Brown CL, Chabot J, Gomes B, Garzone P, Rossi A, Strop P, Shelton D, Pons J, Rajpal A (2012) Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem 287(14):11090–11097

    Article  Google Scholar 

  41. Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, Weikert SH, Presta LG (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277(30):26733–26740

    Article  Google Scholar 

  42. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17(2):176–180

    Article  Google Scholar 

  43. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ, Dahiyat BI (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103(11):4005–4010

    Article  Google Scholar 

  44. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276(9):6591–6604

    Article  Google Scholar 

  45. Sievers EL, Senter PD (2013) Antibody-drug conjugates in cancer therapy. Annu Rev Med 64:15–29

    Article  Google Scholar 

  46. Ducry L, Stump B (2010) Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 21(1):5–13

    Article  Google Scholar 

  47. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blattler WA (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66(8):4426–4433

    Article  Google Scholar 

  48. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, Senter PD (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21(7):778–784

    Article  Google Scholar 

  49. Doronina SO, Bovee TD, Meyer DW, Miyamoto JB, Anderson ME, Morris-Tilden CA, Senter PD (2008) Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug Chem 19(10):1960–1963

    Article  Google Scholar 

  50. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7(6):1490–1496

    Google Scholar 

  51. Katz J, Janik JE, Younes A (2011) Brentuximab Vedotin (SGN-35). Clin Cancer Res 17(20):6428–6436

    Article  Google Scholar 

  52. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate. Cancer Res 68(22):9280–9290

    Article  Google Scholar 

  53. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10(20):7063–7070

    Article  Google Scholar 

  54. Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, Vandlen R, Spencer SD, Scheller RH, Polakis P, Sliwkowski MX (2010) Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 16(19):4769–4778

    Article  Google Scholar 

  55. Jeger S, Zimmermann K, Blanc A, Grunberg J, Honer M, Hunziker P, Struthers H, Schibli R (2010) Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew Chem Int Ed Engl 49(51):9995–9997

    Article  Google Scholar 

  56. Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, Halder R, Forsyth JS, Santidrian AF, Stafin K, Lu Y, Tran H, Seller AJ, Biroc SL, Szydlik A, Pinkstaff JK, Tian F, Sinha SC, Felding-Habermann B, Smider VV, Schultz PG (2012) Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci, USA

    Google Scholar 

  57. Koppe MJ, Postema EJ, Aarts F, Oyen WJ, Bleichrodt RP, Boerman OC (2005) Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev 24(4):539–567

    Article  Google Scholar 

  58. Cornelissen B, Vallis KA (2010) Targeting the nucleus: an overview of Auger-electron radionuclide therapy. Curr Drug Discov Technol 7(4):263–279

    Article  Google Scholar 

  59. Steiner M, Neri D (2011) Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res 17(20):6406–6416

    Article  Google Scholar 

  60. Goldenberg DM, Chang CH, Rossi EA, McBride JW, Sharkey RM (2012) Pretargeted molecular imaging and radioimmunotherapy. Theranostics 2(5):523–540

    Article  Google Scholar 

  61. Hnatowich DJ, Virzi F, Rusckowski M (1987) Investigations of avidin and biotin for imaging applications. J Nucl Med 28(8):1294–1302

    Google Scholar 

  62. Goldenberg DM, Chatal JF, Barbet J, Boerman O, Sharkey RM (2007) Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther 2(1):19–31

    Article  Google Scholar 

  63. Pecking AP, Bellet D, Alberini JL (2012) Immuno-SPET/CT and immuno-PET/CT: a step ahead to translational imaging. Clin Exp Metastasis 29(7):847–852

    Article  Google Scholar 

  64. Yokota T, Milenic DE, Whitlow M, Schlom J (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52(12):3402–3408

    Google Scholar 

  65. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23(9):1126–1136

    Article  Google Scholar 

  66. Holliger P, Prospero T, Winter G (1993) “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90(14):6444–6448

    Article  Google Scholar 

  67. Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, Shively JE, Wu AM (1996) Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56(13):3055–3061

    Google Scholar 

  68. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepulveda J, Burrone O, Neri D, Zardi L (2002) Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 102(1):75–85

    Article  Google Scholar 

  69. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R (1993) Naturally occurring antibodies devoid of light chains. Nature 363(6428):446–448

    Article  Google Scholar 

  70. Kontermann R (2012) Dual targeting strategies with bispecific antibodies. MAbs 4(2):182–197

    Google Scholar 

  71. Karawajew L, Micheel B, Behrsing O, Gaestel M (1987) Bispecific antibody-producing hybrid hybridomas selected by a fluorescence activated cell sorter. J Immunol Methods 96(2):265–270

    Article  Google Scholar 

  72. Ridgway JB, Presta LG, Carter P (1996) ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 9(7):617–621

    Article  Google Scholar 

  73. Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, Ng SB, Born T, Retter M, Manchulenko K, Sweet H, Foltz IN, Wittekind M, Yan W (2010) Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem 285(25):19637–19646

    Article  Google Scholar 

  74. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P (1998) An efficient route to human bispecific IgG. Nat Biotechnol 16(7):677–681

    Article  Google Scholar 

  75. Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, Schwaiger M, Stubenrauch KG, Sustmann C, Thomas M, Scheuer W, Klein C (2011) Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA 108(27):11187–11192

    Article  Google Scholar 

  76. Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, van Berkel PH, van de Winkel JG, Schuurman J, Parren PW (2013) Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A 110(13):5145–5150

    Article  Google Scholar 

  77. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, Fuh G (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323(5921):1610–1614

    Article  Google Scholar 

  78. Linke R, Klein A, Seimetz D (2010) Catumaxomab: clinical development and future directions. MAbs 2(2):129–136

    Article  Google Scholar 

  79. Watts RJ, Dennis MS (2013) Bispecific antibodies for delivery into the brain. Curr Opin Chem Biol

    Google Scholar 

  80. Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhu S, Watts RJ, Dennis MS (2011) Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 3(84):84ra44

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Paul Scherrer Institute (PSI), 5232, Villigen, Switzerland

    Eliane Fischer

Authors
  1. Eliane Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eliane Fischer .

Editor information

Editors and Affiliations

  1. Dept of Radiology/Medical Physics/Biomed, University of Wisconsin, Madison, USA

    Weibo Cai

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Fischer, E. (2014). Antibody Engineering in Translational Medicine. In: Cai, W. (eds) Engineering in Translational Medicine. Springer, London. https://doi.org/10.1007/978-1-4471-4372-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4372-7_11

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4371-0

  • Online ISBN: 978-1-4471-4372-7

  • eBook Packages: EngineeringEngineering (R0)

Publish with us

Policies and ethics

Search

Navigation